Cited 20 times in
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2019-07-23T06:53:51Z | - |
dc.date.available | 2019-07-23T06:53:51Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/170362 | - |
dc.description.abstract | Avelumabis a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastaticgastric/gastroesophageal junctioncancer, including asfirst-linemaintenancetherapy. Here, we describe thedesignofJAVELINGastric100(NCT02625610), an open-label, Phase III trial. A total of 499 patients with locally advanced/metastatic HER2-gastric/gastroesophageal junctioncanceradenocarcinoma, who had achieved at least stable disease following 12 weeks offirst-lineoxaliplatin/fluoropyrimidinechemotherapy, have been randomized 1:1 to receiveavelumabmaintenancetherapy or continuechemotherapy. The primary objective is to demonstrate superior overall survival in all randomized patients or in the PD-L1+population. Secondary objectives are to demonstrate superiority for progression-free survival and objective response rate, compare quality of life measures, and determine safety. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Markus Moehler | - |
dc.contributor.googleauthor | Min-Hee Ryu | - |
dc.contributor.googleauthor | Mikhail Dvorkin | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Hasan Ş Coşkun | - |
dc.contributor.googleauthor | Rachel Wong | - |
dc.contributor.googleauthor | Hyun C Chung | - |
dc.contributor.googleauthor | Artem Poltoratsky | - |
dc.contributor.googleauthor | Akihito Tsuji | - |
dc.contributor.googleauthor | Chia Jui Yen | - |
dc.contributor.googleauthor | Alina S Muntean | - |
dc.contributor.googleauthor | Samuel Le Sourd | - |
dc.contributor.googleauthor | Gina M Vaccaro | - |
dc.contributor.googleauthor | Lindsay Overton | - |
dc.contributor.googleauthor | Narikazu Boku | - |
dc.contributor.googleauthor | Zev A Wainberg | - |
dc.contributor.googleauthor | Manish Patel | - |
dc.contributor.googleauthor | Maitreyi Sharma | - |
dc.contributor.googleauthor | Huiling Xiong | - |
dc.contributor.googleauthor | Ilaria Conti | - |
dc.contributor.googleauthor | Julien Taieb | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.identifier.doi | 10.2217/fon-2018-0668 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00914 | - |
dc.identifier.eissn | 1744-8301 | - |
dc.identifier.pmid | 30379568 | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | avelumab | - |
dc.subject.keyword | gastriccancer | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 567 | - |
dc.citation.endPage | 577 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, Vol.15(6) : 567-577, 2019 | - |
dc.identifier.rimsid | 62726 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.